DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy

Information source: Inonu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anesthesia; ECT

Intervention: Etomidate (Drug); Sevoflurane (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Inonu University

Official(s) and/or principal investigator(s):
Ulku Ozgul, MD, Study Director, Affiliation: Inonu University School of Medicine

Summary

The purpose of the study was to investigate the effects of etomidate or sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles.

Clinical Details

Official title: Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Motor (EMG) seizure duration

electroencephalography (EEG) seizure duration

Secondary outcome:

heart rate (HR),

mean arterial pressure (MAP)

recovery times

Detailed description: Twenty-five patients will be a total of 150 ECT treatments in this prospective, double-blinded, crossover study. Each patient will receive either 0. 2 mg/kg etomidate (Group 1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of consciousness for their initial electroconvulsive therapy session. In subsequent sessions, patients will receive the alternative sevoflurane concentration and then alternated between doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine. Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean arterial pressure (MAP) values, and recovery times will recorde.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Study include 25 patients of American Society of Anesthesiologists (ASA) physical

status I-II aged between 18-60 years who schedule for ECT sessions under general anesthesia Exclusion Criteria:

- Pregnancy

- Cerebrovascular disease

- Epilepsy

- Unstable cardiovascular disease

- Chronic obstructive pulmonary disease; and

- Renal or hepatic failure

Locations and Contacts

Additional Information

Starting date: July 2015
Last updated: July 15, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017